Immunogenic cell death inducing metal complexes for cancer therapy
L Zhang, N Montesdeoca, J Karges… - Angewandte Chemie …, 2023 - Wiley Online Library
Cancer is one of the deadliest diseases worldwide. Recent statistics have shown that
metastases and tumor relapse are the leading causes of cancer‐associated deaths. While …
metastases and tumor relapse are the leading causes of cancer‐associated deaths. While …
Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
Cancer is the deadliest disease in the world behind heart disease. Sadly, this remains true
even as we suffer the ravages of the Covid-19 pandemic. Whilst current chemo-and …
even as we suffer the ravages of the Covid-19 pandemic. Whilst current chemo-and …
An ER‐targeting iridium (III) complex that induces immunogenic cell death in non‐small‐cell lung cancer
L Wang, R Guan, L Xie, X Liao, K Xiong… - Angewandte …, 2021 - Wiley Online Library
Immunogenic cell death (ICD) is a vital component of therapeutically induced anti‐tumor
immunity. An iridium (III) complex (Ir1), containing an N, N‐bis (2‐chloroethyl)‐azane …
immunity. An iridium (III) complex (Ir1), containing an N, N‐bis (2‐chloroethyl)‐azane …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia… - Nature reviews Clinical …, 2023 - nature.com
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
Trial watch: chemotherapy-induced immunogenic cell death in oncology
Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
Target profiling of an iridium (III)-based immunogenic cell death inducer unveils the engagement of unfolded protein response regulator BiP
Clinical chemotherapeutic drugs have occasionally been observed to induce antitumor
immune responses beyond the direct cytotoxicity. Such effects are coined as immunogenic …
immune responses beyond the direct cytotoxicity. Such effects are coined as immunogenic …
Upregulating aggregation‐induced‐emission nanoparticles with blood–tumor‐barrier permeability for precise photothermal eradication of brain tumors and induction …
M Zhang, W Wang, M Mohammadniaei… - Advanced …, 2021 - Wiley Online Library
Compared to other tumors, glioblastoma (GBM) is extremely difficult to treat. Recently,
photothermal therapy (PTT) has demonstrated advanced therapeutic efficacy; however …
photothermal therapy (PTT) has demonstrated advanced therapeutic efficacy; however …
Potent Zinc(II)-Based Immunogenic Cell Death Inducer Triggered by ROS-Mediated ERS and Mitochondrial Ca2+ Overload
LS Liao, Y Chen, C Hou, YH Liu, GF Su… - Journal of Medicinal …, 2023 - ACS Publications
Zn1 and Zn2 are Zn-based complexes that activate the immunogenic cell death (ICD) effect
by Ca2+-mediated endoplasmic reticulum stress (ERS) and mitochondrial dysfunction …
by Ca2+-mediated endoplasmic reticulum stress (ERS) and mitochondrial dysfunction …
Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect
R Luo, K Onyshchenko, L Wang, S Gaedicke… - Clinical Cancer …, 2023 - AACR
Purpose: Cisplatin is increasingly used in chemoimmunotherapy and may enhance the T
cell–dependent radiation-induced abscopal effect, but how it promotes antitumor immunity is …
cell–dependent radiation-induced abscopal effect, but how it promotes antitumor immunity is …
Macrophages as a potential immunotherapeutic target in solid cancers
The revolution in cancer immunotherapy over the last few decades has resulted in a
paradigm shift in the clinical care of cancer. Most of the cancer immunotherapeutic regimens …
paradigm shift in the clinical care of cancer. Most of the cancer immunotherapeutic regimens …